The Board has approved the Re-appointment of Mr. Sanker Parameswaran (DIN:- 00008187) as an Independent Director for second(02nd) term of five (5) years subject to the approval of the members.
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India's board met on May 9, 2025 and approved several items in one go. The audited financial results for Q4 and the full financial year ended March 31, 2025 were taken on record, along with an unmodified audit opinion from the statutory auditors. The board has recommended a final dividend of INR 25 per equity share (on a face value of INR 5), pending shareholder approval at the AGM. Mr. Sanker Parameswaran (DIN 00008187) has been re-appointed as an Independent Non-Executive Director for a second 5-year term from June 22, 2025 to June 21, 2030, subject to shareholder approval via postal ballot. The board also appointed M K Saraf & Associates LLP as Secretarial Auditors for 5 years starting April 1, 2025, and set July 31, 2025 as the date for the 77th AGM.
For shareholders, the key takeaways are the INR 25 per share final dividend (a 500% payout on face value) and confirmation of FY25 audited results with a clean audit report, both of which are routine positive signals. The director re-appointment and new secretarial auditor are standard governance actions and unlikely to move the stock meaningfully.